{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:42:20Z","timestamp":1777138940353,"version":"3.51.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s43441-026-00938-8","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:38:44Z","timestamp":1772033924000},"page":"893-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimand Framework Development for eGFR Slope Estimation and Comparative Analyses Across Various Estimation Methods"],"prefix":"10.1007","volume":"60","author":[{"given":"Tuo","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"key":"938_CR1","unstructured":"European Medicines Agency. Qualification opinion on gfr slope as a validated surrogate endpoint in rcts for ckd. 2023."},{"key":"938_CR2","doi-asserted-by":"crossref","unstructured":"Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, et al. Evaluating glomerular filtration rate slope as a surrogate end point for eskd in clinical trials: an individual participant meta-analysis of observational data. 2019.","DOI":"10.1681\/ASN.2019010008"},{"key":"938_CR3","doi-asserted-by":"crossref","unstructured":"Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, et al. Performance of gfr slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation. 2019.","DOI":"10.1681\/ASN.2019010009"},{"key":"938_CR4","doi-asserted-by":"crossref","unstructured":"Group E-KC. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","DOI":"10.1056\/NEJMoa2204233"},{"issue":"15","key":"938_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJ Heerspink","year":"2020","unstructured":"Heerspink HJ, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"key":"938_CR6","unstructured":"Holst KK, Nordland A, Furberg JF, Damgaard LH, Pipper CB. A retake on the analysis of scores truncated by terminal events. 2025. arXiv:2502.03942."},{"key":"938_CR7","unstructured":"Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Font\u00e1n F, Del Vecchio L, Floege J, et al. A meta-analysis of gfr slope as a surrogate endpoint for kidney failure. Nature Med. 2023:1\u201310."},{"issue":"9","key":"938_CR8","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1681\/ASN.2019010007","volume":"30","author":"LA Inker","year":"2019","unstructured":"Inker LA, Heerspink HJ, Tighiouart H, Levey AS, Coresh J, Gansevoort RT, et al. Gfr slope as a surrogate end point for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials. J Am Soc Nephrol. 2019;30(9):1735.","journal-title":"J Am Soc Nephrol"},{"key":"938_CR9","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Statistical principles for clinical trials: addendum: estimands and sensitivity analysis in clinical trials. Guideline. 2021;E9(R1)."},{"issue":"9888","key":"938_CR10","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888):260\u201372.","journal-title":"The Lancet"},{"issue":"5","key":"938_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1001\/jamacardio.2021.5151","volume":"7","author":"MS Khan","year":"2022","unstructured":"Khan MS, Bakris GL, Shahid I, Weir MR, Butler J. Potential role and limitations of estimated glomerular filtration rate slope assessment in cardiovascular trials: a review. JAMA Cardiol. 2022;7(5):549\u201355.","journal-title":"JAMA cardiology"},{"issue":"1","key":"938_CR12","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","volume":"75","author":"AS Levey","year":"2020","unstructured":"Levey AS, Gansevoort RT, Coresh J, Inker LA, Heerspink HL, Grams ME, et al. Change in albuminuria and gfr as end points for clinical trials in early stages of ckd: a scientific workshop sponsored by the national kidney foundation in collaboration with the us food and drug administration and european medicines agency. Am J Kidney Dis. 2020;75(1):84\u2013104.","journal-title":"Am J Kidney Dis"},{"issue":"24","key":"938_CR13","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"2","key":"938_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JF, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"4","key":"938_CR15","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. Kdigo 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105(4):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"1","key":"938_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","volume":"75","author":"A Thompson","year":"2020","unstructured":"Thompson A, Smith K, Lawrence J. Change in estimated gfr and albuminuria as end points in clinical trials: a viewpoint from the fda. Am J Kidney Dis. 2020;75(1):4\u20135.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"938_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle KR, Lakshmanan MC, Rayner B, Busch RS, Zimmermann AG, Woodward DB, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (award-7): a multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology. 2018;6(8):605\u201317.","journal-title":"The Lancet Diabetes & Endocrinology"},{"issue":"9","key":"938_CR18","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jclinepi.2006.02.007","volume":"59","author":"GJ Van Breukelen","year":"2006","unstructured":"Van Breukelen GJ. Ancova versus change from baseline had more power in randomized studies and more bias in nonrandomized studies. J Clin Epidemiol. 2006;59(9):920\u20135.","journal-title":"J Clin Epidemiol"},{"issue":"7321","key":"938_CR19","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","volume":"323","author":"AJ Vickers","year":"2001","unstructured":"Vickers AJ, Altman DG. Analysing controlled trials with baseline and follow up measurements. BMJ. 2001;323(7321):1123\u20134.","journal-title":"BMJ"},{"issue":"22","key":"938_CR20","doi-asserted-by":"publisher","first-page":"4218","DOI":"10.1002\/sim.8282","volume":"38","author":"E Vonesh","year":"2019","unstructured":"Vonesh E, Tighiouart H, Ying J, Heerspink HL, Lewis J, Staplin N, et al. Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease. Stat Med. 2019;38(22):4218\u201339.","journal-title":"Stat Med"},{"issue":"1","key":"938_CR21","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/biom.13438","volume":"78","author":"EF Vonesh","year":"2022","unstructured":"Vonesh EF, Greene T. Biased estimation with shared parameter models in the presence of competing dropout mechanisms. Biometrics. 2022;78(1):399\u2013406.","journal-title":"Biometrics"},{"issue":"10075","key":"938_CR22","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/S0140-6736(16)32064-5","volume":"389","author":"AC Webster","year":"2017","unstructured":"Webster AC, Nagler EV, Morton RL, Masson P. Chronic kidney disease. The Lancet. 2017;389(10075):1238\u201352.","journal-title":"The Lancet"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00938-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00938-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T17:26:44Z","timestamp":1777138004000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00938-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["938"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00938-8","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no Conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}